Neurocrine Biosciences Inc.
19
11
14
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 5/100
5.3%
1 terminated/withdrawn out of 19 trials
68%
13 trials in Phase 3/4
100%
2 of 2 completed trials have results
Key Signals
Enrollment reporting
Analytics
Activity Timeline
Global Presence
Clinical Trials (19)
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Role: lead
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Role: lead
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Role: lead
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Role: lead
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Role: lead
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Role: lead
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
Role: lead
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
Role: lead
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Role: lead
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Role: lead
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Role: lead
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Role: lead
Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Participants With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)
Role: lead
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
Role: lead
Effect of NBI-921355 on corticospinal excitability in healthy participants
Role: lead
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1117570 in Healthy Adults
Role: lead
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
Role: lead
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-1076986 in Healthy Adults.
Role: lead
An open-label study to evaluate the effect of crinecerfont on androgen reduction and related outcomes in adults with classic CAH
Role: lead
All 19 trials loaded